Year: 2025

NEWBURYPORT, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) — UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported net income of $16.4 million or $2.11 per diluted common share outstanding for its third quarter ended September 30, 2025, the same as in Q3 of 2024. Adjusted earnings per diluted share outstanding for the third quarter ended September 30, 2025, was $2.39. Sales for the third quarter were $154.6 million compared to sales of $145.2 million in the third quarter of 2024. Net income for the nine-month period ended September 30, 2025, was $50.7 million or $6.52 per diluted common share outstanding compared to net income of $42.6 million or $5.49 per diluted common share outstanding for the same period in 2024....

Conference Call and Webcast scheduled for tomorrow, November 4, 2025 at 10:00 am PT SAN JUAN CAPISTRANO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign(TM) group of companies, which provide post-acute healthcare services and invest in the long-term healthcare industry, primarily in skilled nursing and senior living facilities, announced operating results for the third quarter of 2025, reporting GAAP diluted earnings per share of $1.42 and adjusted earnings per share(1) of $1.64, both for the quarter ended September 30, 2025. Highlights Include:GAAP diluted earnings per share for the quarter was $1.42, an increase of 6.0% over the prior year quarter, and adjusted diluted earnings per share(1) for the quarter was $1.64, an increase of 18.0% over the prior year quarter. GAAP...

Delivered Q3 2025 revenue of $83 million Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024 Q3 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 36% over Q3 2024 Raising full-year 2025 revenue guidance to $327-335 million from $310-320 million Announced launch of AdvanceAD-Tx™, the Company’s test designed to guide systemic treatment decision making in patients ages 12 and older with moderate-to-severe atopic dermatitis (AD) Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended Sept. 30, 2025. “We delivered a strong...

All results reported are for continuing operations, unless otherwise noted.Record quarterly revenue of $82.2 million, representing an increase of 34% year-over-year Quarterly gross margin of 79.4% and an increase in gross profit of 34% year-over-year Active Buyers of 1.57 million, representing growth of 26% year-over-year, with new buyer growth of 54% year-over-year, reflecting ThredUp’s best quarter for new buyer acquisition in its history Ended the quarter with cash and cash equivalents, restricted cash, and marketable securities of $56.1 million, substantially consistent with the $56.2 million reported last quarter Issued a revised fourth quarter and full year 2025 financial outlook, raising revenue expectationsOAKLAND, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — ThredUp Inc. (Nasdaq: TDUP, LTSE: TDUP), one of the largest...

Third Quarter Revenue Growth of 20% Year-Over-Year to $173.9 million Record Third Quarter Net Income up 63% Year-Over-Year to $18.9 million Record Adjusted EBITDA Increases 33% Year-Over-Year to $25.1 millionCAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) — EverQuote, Inc. (Nasdaq: EVER), a leading online insurance marketplace, today announced financial results for the third quarter ended September 30, 2025. “In the third quarter, we achieved record top and bottom line performance and we are making steady progress towards our vision of becoming the leading growth partner to P&C insurance providers,” said Jayme Mendal, CEO of EverQuote. “We are innovating new products, releasing features and further embedding AI into our marketplace to accelerate our transformation from a lead generation vendor to a multi-product, AI-powered...

HighlightsThird quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations. Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively. Third quarter 2025 gross margin was 69.9%. Third quarter 2025 GAAP net loss of $27.4 million, or $0.29 per share, while adjusted EPS was $0.00. Third quarter 2025 adjusted EBITDA was $10.3 million. Entered a strategic collaboration with SOPHiA GENETICS (Nasdaq: SOPH) to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) testing solution.SALT LAKE CITY, Nov. 03, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic...

– Total net sales of $138.5 million, compared to $149.7 million in prior year third quarter –– Net income of $2.7 million, compared to $5.4 million in prior year third quarter –– EBITDA of $7.5 million, compared to $11.7 million in prior year third quarter –– Board of Directors approves $0.14 per share quarterly dividend – ST. PETERSBURG, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) — Superior Group of Companies, Inc. (NASDAQ: SGC) (the “Company”), today announced its third quarter 2025 results. “Our earnings were as expected, demonstrating solid sequential progress from the second quarter and our updated full-year outlook reflects a higher mid-point,” said Michael Benstock, Chief Executive Officer. “We were also able to meaningfully improve SG&A, which bodes well for future profitability as greater economic clarity...

NASHVILLE, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) — Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2025 financial results after the market closes on Monday, November 10, 2025. iMDx will host a live Zoom webinar to discuss the company’s financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: iMDX Q3 2025 Earnings Webinar. An archived replay will be available after the call concludes on iMDX’s investor relations website at  https://investors.imdxinc.com/. Stephens NASH25 ConferenceSeparately, on November 19th, Chief Executive Officer Josh Riggs will attend the Stephens NASH25 Conference, taking place from November 18-20, 2025. Investors...

Management to Host Conference Call Tomorrow at 8:30 a.m. ET NORWALK, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) — Reed’s, Inc. (OTCQX: REED) (“Reed’s” or the “Company”), owner of the nation’s leading portfolio of handcrafted, natural ginger beverages, is reporting financial results for the three and nine months ended September 30, 2025. Q3 2025 Financial Highlights (vs. Q3 2024):Net sales increased 4% to $7.0 million compared to $6.8 million. Gross profit remained flat at $1.2 million, with gross margin of 17% compared to 18%. Excluding inventory write-offs of $0.1 million, gross profit for the third quarter of 2025 was $1.3 million with gross margin of 19%. Delivery and handling costs decreased by 14% to $2.50 per case compared to $2.99 per case. Selling, general and administrative expenses were $4.2 million compared to $3.1 million. Net...

PEMBROKE, Bermuda, Nov. 03, 2025 (GLOBE NEWSWIRE) — James River Group Holdings, Ltd. (“James River” or the “Company”) (NASDAQ: JRVR) reported a net loss from continuing operations available to common shareholders of $0.4 million, or ($0.01) per diluted share, compared to a net loss from continuing operations available to common shareholders of ($40.7 million), or ($1.07) per diluted share, for the same 2024 period. Adjusted net operating income1 for the third quarter of 2025 was $17.4 million or $0.32 per diluted share, compared to ($28.2 million), or ($0.74) per diluted share, for the same 2024 period.  Three Months EndedSeptember 30,   Three Months EndedSeptember 30,($ in thousands, except for share data)   2025     per diluted share     2024     per diluted shareNet loss from continuing operations...